Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids.

With the ongoing public health crisis with prescription opioids, there is a need for safer alternatives for medication management in chronic pain patients. Buprenorphine is a partial mu-opioid agonist which is commonly utilized to treat patients with opioid-use disorders. The purpose of this review is to discuss the potential use of this medication for the treatment of chronic pain instead of resorting to more traditional Schedule II opioids. Buprenorphine offers a safer alternative for patients who require opioids to manage chronic pain, given the unique pharmacological properties that allow it to provide adequate analgesia with less abuse potential.

[1]  J. Fudin,et al.  A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain , 2020, Pain and Therapy.

[2]  A. Sahraian,et al.  A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving , 2019, Trials.

[3]  J. Pergolizzi,et al.  Pain Control in Latin America: The Optimized Role of Buprenorphine in the Treatment of Cancer and Noncancer Pain , 2019, Pain and Therapy.

[4]  G. Guyatt,et al.  Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis , 2018, JAMA.

[5]  M. Fishman,et al.  Buprenorphine for Chronic Pain: a Systemic Review , 2018, Current Pain and Headache Reports.

[6]  James M. Dahlhamer,et al.  Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016 , 2018, MMWR. Morbidity and mortality weekly report.

[7]  G. Pasternak,et al.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option , 2018, Drugs.

[8]  D. Yoon,et al.  Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain , 2017, BMC Musculoskeletal Disorders.

[9]  L. Baker,et al.  Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis , 2017, British Medical Journal.

[10]  A. Kadakia,et al.  Buprenorphine transdermal system utilization , 2017, Postgraduate medicine.

[11]  R. Simpson,et al.  Transdermal Buprenorphine Relieves Neuropathic Pain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Diabetic Peripheral Neuropathic Pain , 2016, Diabetes Care.

[12]  Roger Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  R. Raffa,et al.  Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate‐to‐Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials , 2016, Pain practice : the official journal of World Institute of Pain.

[14]  A. Finn,et al.  Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine , 2016, Pain medicine.

[15]  A. Finn,et al.  Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. , 2016, Clinical therapeutics.

[16]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[17]  A. Finn,et al.  Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain , 2016, Postgraduate medicine.

[18]  P. Wiffen,et al.  Buprenorphine for neuropathic pain in adults. , 2015, The Cochrane database of systematic reviews.

[19]  P. Mehler,et al.  Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. , 2015, Addiction.

[20]  L. Webster,et al.  Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study. , 2015, Clinical therapeutics.

[21]  P. Fudala,et al.  Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers , 2015, Clinical Pharmacokinetics.

[22]  H. Ono,et al.  The clinical analgesic efficacy of buprenorphine , 2014, Journal of clinical pharmacy and therapeutics.

[23]  Joyce M. Cote,et al.  Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. , 2014, Pain medicine.

[24]  Jean-Pierre Amorij,et al.  Buccal and sublingual vaccine delivery , 2014, Journal of Controlled Release.

[25]  Cho Naing,et al.  A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain , 2014, SpringerPlus.

[26]  Mellar P. Davis.  Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. , 2012, The journal of supportive oncology.

[27]  J. Pergolizzi,et al.  Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. , 2012, Pain physician.

[28]  N. Al-Tawil,et al.  Pharmacokinetics of transdermal buprenorphine patch in the elderly , 2012, European Journal of Clinical Pharmacology.

[29]  P. Conaghan,et al.  Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. , 2011, Osteoarthritis and cartilage.

[30]  G. Pasternak,et al.  Mu opioid receptors in pain management. , 2011, Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists.

[31]  Albert Dahan,et al.  Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile , 2010, Pain practice : the official journal of World Institute of Pain.

[32]  I. James,et al.  A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. , 2010, Journal of pain and symptom management.

[33]  Herman Joseph,et al.  Opioids and the treatment of chronic pain: controversies, current status, and future directions. , 2008, Experimental and clinical psychopharmacology.

[34]  A. Dahan,et al.  Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone) , 2008, Pain practice : the official journal of World Institute of Pain.

[35]  J. Schüttler,et al.  Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine , 2006, European journal of pain.

[36]  C. Welsh,et al.  Managing opioid addiction with buprenorphine. , 2006, American family physician.

[37]  P. Pade,et al.  Effect of Buprenorphine and Antiretroviral Agents on the QT Interval in Opioid-Dependent Patients , 2006, The Annals of pharmacotherapy.

[38]  D. Ciraulo,et al.  Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose‐Escalation Trials , 2006, Journal of clinical pharmacology.

[39]  A. Dahan.  Opioid-induced respiratory effects: new data on buprenorphine , 2006, Palliative medicine.

[40]  S. Walsh,et al.  The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. , 2003, Drug and alcohol dependence.

[41]  Reese T. Jones,et al.  Bioavailability of Sublingual Buprenorphine , 1997, Journal of clinical pharmacology.

[42]  S. Schug,et al.  The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine , 2019, Pain medicine.

[43]  H. Breivik,et al.  Buprenorphine 5, 10 and 20lg/h Transdermal Patch A Review of its Use in the Management of Chronic Non-Malignant Pain , 2011 .

[44]  F. De Conno,et al.  WHO guidelines for the use of analgesics in cancer pain. , 1985, International journal of tissue reactions.